Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

Ignore these popular cannabis stocks and buy the only Canadian grower that's managed to deliver a no-nonsense profit.

Forget Aurora, Canopy, and Cronos: This Is the Only Canadian Pot Stock to Buy

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

Aurora Cannabis

Canopy Growth

Tilray Brands

When pot stocks failed to live up to heightened expectations, investors panicked out of the sector.

10 Hot Pot Stocks to Buy

Although Cronos Group stock distinguishes itself in the embattled cannabis sector, it too makes some assumptions about future growth potential that may not suit all investors.
The post Cronos Group Remains a Different Kind of Cannabis Company appeared first on InvestorPlace.

Cronos Group Remains a Different Kind of Cannabis Company

Aphria

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

GW Pharmaceuticals

Trulieve Cannabis Corp.

Marijuana stock market caps continue to shrink.

There Are Only 9 Billion-Dollar Pot Stocks Left

With the MORE Act unlikely to pass Congress, and supply issues still plaguing Canada, you can find better opportunities elsewhere.
The post Cronos Stock Will Not Rebound Any Time Soon appeared first on InvestorPlace.

Cronos Stock Will Not Rebound Any Time Soon

Marijuana legalization in the US looks unlikely in the near-term, but investors should be keeping an eye on these 4 marijuana stocks for the future of the market.
The post 4 Marijuana Stocks to Own If the U.S.

4 Marijuana Stocks to Own If the U.S. Legalizes Pot

HEXO Corp

Is It Time To Get Bullish On Green Bud?

Cronos stock long has been the pot stock for investors who don't like pot stocks. That might be enough for a buy at some point.

Cronos Stock Gets Closer to Being a Buy, but It’s Not There Yet

Amplify Alternative Harvest ETF

Pot stocks are unlikely to turn around long term until regulators allow the industry to breathe.

Cannabis Tax Regimes Need To Change Before The Sector Can Take Off

Marijuana stocks fell after the FDA said it cannot conclude that CBD is "recognized as safe" in food, and that many unanswered questions remain about CBD.

Marijuana Stocks Fall As FDA Warns Of CBD Risk

These 17 marijuana stocks are collectively crushing investors' hopes and dreams.

Pot Stocks Have Cost Investors $40 Billion (on Paper) Over the Past 7 Months

This morning, I am recommending a bearish trade on Cronos Group, Inc. (NASDAQ:CRON), the vertically integrated cannabis company.

Decriminalization Won’t Pass the Senate, and Cronos Will Come Back Down

CRON stock should become an eventual winner for investors, but the rally sparked by the vote in the U.S. House will likely not last.

Don’t Buy Cronos Stock on the U.S. House Committee Vote

The landmark legislation could pave the way for weed to become legal at the federal level.

Cannabis Stocks Soar as Bill to Legalize Marijuana Approved

A huge milestone toward legalizing marijuana in the U.S. is providing a big catalyst for Canadian marijuana stocks.

Why Marijuana Stocks Aurora Cannabis, Canopy Growth, Cronos Group, HEXO, and OrganiGram Are Crushing It Today

Cronos stock could pay off handsomely for patient investors, but the road ahead is highly uncertain.

Is  Cronos Group  Stock a Buy?

Cronos stock started out pretty hot, but recent developments (or the lack thereof) make it a pot stock you want to avoid.

Add Cronos Stock to the List of Canadian Pot Stocks to Avoid

Cronos Group ended the third quarter with $1.51 billion in cash, cash equivalents, and marketable securities, but has a market cap of less than $2.2 billion.

Could Cronos Group Stock Fall Below Its Cash Value?

Cronos (CRON) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Cronos (CRON) Catches Eye: Stock Jumps 9.1%

CannTrust Holdings

This Billionaire Money Manager Bought 6 Cannabis Stocks in the Third Quarter

OrganiGram Holdings Inc.

One retail cannabis store for every 600,000 residents simply isn't enough in Canada's heaviest-populated province.

Blame It on Ontario: Why 1 Province Is the Main Culprit Behind the Canadian Cannabis Industry's Woes

With marijuana legalized in Canada, these penny stocks offer direct exposure and could help you get a piece of the pot.

10 Canadian Marijuana Stocks for Your Portfolio

Cronos Group's latest financial results weren’t particularly good, but here’s what investors should keep an eye on.

Here’s the Most Encouraging Sign in Cronos Group's Latest Earnings Report

Marijuana stocks have been gutted this year. But a new survey finds that believers still exist — even if fewer of them make money on the industry.

Marijuana Stocks Are Flailing, But Survey Finds Believers Hang On

News for Cronos Group Stock (CRON)